Kanak V. Kennedy MD , Anna Costello MD , Melissa A. Lerman MD, PhD , Jon M. Burnham MD , Aoife Corcoran MD , Joseph Piccione DO , Alexandra Grier MD, PhD , Kathleen Sullivan MD, PhD , Terri Whitehorn-Brown MD , Caitlin J. Alexander MD , Laura S. Finn MD , Benjamin J. Wilkins MD, PhD , Amanda B. Muir MD
{"title":"Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitis","authors":"Kanak V. Kennedy MD , Anna Costello MD , Melissa A. Lerman MD, PhD , Jon M. Burnham MD , Aoife Corcoran MD , Joseph Piccione DO , Alexandra Grier MD, PhD , Kathleen Sullivan MD, PhD , Terri Whitehorn-Brown MD , Caitlin J. Alexander MD , Laura S. Finn MD , Benjamin J. Wilkins MD, PhD , Amanda B. Muir MD","doi":"10.1016/j.jacig.2024.100314","DOIUrl":null,"url":null,"abstract":"<div><p>We present the first case of a dupilumab-induced hyperinflammatory state in the setting of underlying eosinophilic esophagitis characterized by multisystem granulomatous inflammation. Although clinical trial data and subsequent real-world experience support dupilumab as a highly effective therapy for eosinophilic esophagitis, close monitoring for development of adverse symptoms following initiation remains paramount.</p></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100314"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001103/pdfft?md5=511687d188c2e37b4f58375efad84610&pid=1-s2.0-S2772829324001103-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of allergy and clinical immunology. Global","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772829324001103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
We present the first case of a dupilumab-induced hyperinflammatory state in the setting of underlying eosinophilic esophagitis characterized by multisystem granulomatous inflammation. Although clinical trial data and subsequent real-world experience support dupilumab as a highly effective therapy for eosinophilic esophagitis, close monitoring for development of adverse symptoms following initiation remains paramount.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
